Table 2 Use of MSCs to promote engraftment in large animal models

Human CD34⁺BM cells

Fetal sheep xenograft

None; n/a

Human autologous & allogeneic BM

5 × 10⁴ - 7.5 × 10⁵

Increased engraftment in PB and BM, no difference between autologous & allogeneic

16

Haploidentical BM cells

Canine

9.2 Gy; n/a

Allogeneic BM (3rd party), immortalized clonal populations or primary MSC culture

3 dosing schedules: 30 × 10⁶/kg 3×/wk ×1 wk, then 2×/wk; 15 × 10⁶/kg 5×/wk; 1 × 10⁶/kg 3×/wk

No effect; 50 % graft rejection & 50 % fatal acute GVHD

26

DLA-identical BM cells

Canine

1 Gy; MMF and CSA

Donor-derived BM

1.2 - 1.8 × 10⁶/kg day 0, 1.1 - 1.3 × 10⁶/kg day 35

No effect, uniform graft rejection at median of 8 weeks after initial donor engraftment

27

Autologous CD34⁺ BM cells (intra-BM)

Nonhuman primate

5.5 Gy ×2 doses or Bu; n/a

Autologous BM

NR

1.6-6 fold increase in donor CFUs in BM

28